
RaySearch Laboratories (Q3 Review) - EBIT beat reinforces take on conservative targets

RaySearch's Q3 increases our confidence in its potential for profitable sales growth, with accelerating sales drivers as we move into 2026. Though we urge a long-term perspective (given the lumpiness of the business), quarterly reports remain the main trigger to take the share toward our SEK370 base case.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

RaySearch Laboratories (Q3 Review) - EBIT beat reinforces take on conservative targets